Picture 1 of 14
Gallery
Picture 1 of 14
CNS Neuroprotectio
US $280.00
ApproximatelyPHP 15,607.20
Condition:
Brand New
A new, unread, unused book in perfect condition with no missing or damaged pages.
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
Shipping:
Free USPS Media MailTM.
Located in: Picayune, Mississippi, United States
Delivery:
Estimated between Thu, 12 Jun and Tue, 17 Jun to 94104
Returns:
No returns accepted.
Coverage:
Read item description or contact seller for details. See all detailsSee all details on coverage
(Not eligible for eBay purchase protection programmes)
Seller assumes all responsibility for this listing.
eBay item number:396058463328
Item specifics
- Condition
- Brand New: A new, unread, unused book in perfect condition with no missing or damaged pages. See all condition definitionsopens in a new window or tab
- Book Title
- CNS Neuroprotection
- ISBN
- 9783642076251
About this product
Product Identifiers
Publisher
Springer Berlin / Heidelberg
ISBN-10
3642076254
ISBN-13
9783642076251
eBay Product ID (ePID)
109292598
Product Key Features
Number of Pages
Xxii, 500 Pages
Publication Name
Cns Neuroprotection
Language
English
Publication Year
2010
Subject
Neurology, Life Sciences / Neuroscience, Pharmacology
Type
Textbook
Subject Area
Science, Medical
Series
Handbook of Experimental Pharmacology Ser.
Format
Trade Paperback
Dimensions
Item Weight
31 Oz
Item Length
9.3 in
Item Width
6.1 in
Additional Product Features
Intended Audience
Scholarly & Professional
Dewey Edition
21
Series Volume Number
155
Number of Volumes
1 vol.
Illustrated
Yes
Dewey Decimal
615/.5 s 616.8/0461
Table Of Content
Section I: Mechanic Approaches to CNS Neuroprotection.- 1 Blocking Excitotoxicity.- 2 Limiting Apoptosis as a Strategy for CNS Neuroprotection.- 3 Reducing Neuroinflammation.- 4 Mitochondrial Approaches to Neuroprotection.- 5 Stabilizing Calcium Homeostasis.- 6 Blocking Nitric Oxide Toxicity.- Section II: Neuroprotective Agents.- 7 Adenosine-Based Approaches to the Treatment of Neurodegenerative Disease.- 8 Sodium and Calcium Channel Blockers.- 9 Neuroprotection by Free Radical Scavengers and Other Antioxidants.- 10 Chemokines and Chemokine Receptors in the Central Nervous System: New Opportunities for Novel Therapeutics in Brain Ischemia and Trauma.- Section III: CNS Delivery of Neuroprotective Therapies.- 11 Ex Vivo Gene Therapy in the Central Nervous System.- 12 Developing Gene-Based Neuroprotection Strategies Using Herpes Amplicon Vectors.- Section IV: Disease Targetily of Newoportective Therapies.- 13 Stroke.- 14 Traumatic Central Nervous System Injury.- 15 Neurohormonal Signalling Pathways and the Regulation of Alzheimer ?-amyloid Metabolism Integrating Basic and Clinical Observations for Developing Successful Strategies to Delay, Retard or Prevent Cerebral Amyloidosis in Alzheimer's Disease.- 16 Amyotrophic Lateral Sclerosis.- 17 Therapeutics in Huntington's Disease.
Synopsis
"CNS neuroprotection" was a common subject of papers, symposia, and reviews during the previous "decade of the brain. " Indeed, in recent years, experimental study of putative neuroprotective agents prompted clinical trials of numerous drug candidates in acute and chronic human neurodegenerative conditions. While the outcomes of these trials have not been as successful as initially hoped, these were early explorations, and the pipeline of relevant ideas continues to grow in strength and depth. We predict that early in this new millennium, crippling disorders such as stroke and Alzheimer's disease will be treated effectively by therapeutic neuroprotective strategies. This volume of the Handbook of Experimental Pharmacology titled eNS Neuroprotection provides a pharmacological perspective on currently promis- ing neuroprotective approaches, and a clinical perspective on the challenges involved in establishing the efficacy of these approaches through appropriate clinical trials. Section I, "Mechanistic Approaches to CNS Neuroprotection," reviews major injury mechanisms that have formed the basis for many past and present clinical trials conducted around the world. Dr. KIM and colleagues, Washington University School of Medicine, review the status of blocking excitotoxicity as an approach to CNS neuroprotection. Dr. WANG, Pfizer Global Research and Development, Ann Arbor Laboratories, outlines evidence supporting a contri- bution of apoptosis to pathological neuronal or glial cell loss. Drs. BECKER and HALLENBECK, University of Washington and the National Institute on Neuro- logical Diseases and Stroke, respectively, argue that inhibiting inflammatory pathways in the brain can be neuroprotective. Dr., "CNS neuroprotection" was a common subject of papers, symposia, and reviews during the previous "decade of the brain. " Indeed, in recent years, experimental study of putative neuroprotective agents prompted clinical trials of numerous drug candidates in acute and chronic human neurodegenerative conditions. While the outcomes of these trials have not been as successful as initially hoped, these were early explorations, and the pipeline of relevant ideas continues to grow in strength and depth. We predict that early in this new millennium, crippling disorders such as stroke and Alzheimer's disease will be treated effectively by therapeutic neuroprotective strategies. This volume of the Handbook of Experimental Pharmacology titled eNS Neuroprotection provides a pharmacological perspective on currently promis ing neuroprotective approaches, and a clinical perspective on the challenges involved in establishing the efficacy of these approaches through appropriate clinical trials. Section I, "Mechanistic Approaches to CNS Neuroprotection," reviews major injury mechanisms that have formed the basis for many past and present clinical trials conducted around the world. Dr. KIM and colleagues, Washington University School of Medicine, review the status of blocking excitotoxicity as an approach to CNS neuroprotection. Dr. WANG, Pfizer Global Research and Development,Ann Arbor Laboratories, outlines evidence supporting a contri bution of apoptosis to pathological neuronal or glial cell loss. Drs. BECKER and HALLENBECK, University of Washington and the National Institute on Neuro logical Diseases and Stroke, respectively, argue that inhibiting inflammatory pathways in the brain can be neuroprotective. Dr., This volume is a review which presents both a basic science and clinical perspective on neuroprotective approaches to acute and chronic neurodegenerative conditions. Experts from both fields review current areas of neuroprotection. The book describes basic science discovery in stroke research and the application of research within industry leading to the development of neuroprotective drugs.
LC Classification Number
RM300-666
Item description from the seller
Seller feedback (7,156)
- e***n (259)- Feedback left by buyer.Past monthVerified purchaseGreat price and fast shipping
- d***1 (1907)- Feedback left by buyer.Past monthVerified purchaseLove this product . Great packaging
- 3***9 (85)- Feedback left by buyer.Past monthVerified purchaseA very good experience as pictured and described, well packaged and on time delivery I would purchase from again.